Cohen Joshua B sold $981K of AMLX
Cohen Joshua B (Co-Chief Executive Officer) sold 30,464 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.19 ($32.16–$33.15, $0.98M total) across 2 trades on 2026-09-10.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and unlikely to affect AMLX's stock price significantly.
Market read
Routine insider sale with limited trading relevance.
What to watch
CFO may be diversifying holdings; no change in company fundamentals reported.
Background
SEC Form 4 filing discloses insider transactions; required for public companies.
Ticker impact
Co-CEO Joshua B. Cohen sold 30,464 AMLX shares for $980.5K on 2026-09-10.
Limited short-term pressure; unlikely to move price materially.
The sale represents less than 1% of total holdings and is under $1M, so market reaction is expected to be muted.
Market effects
No broader sector impact; insider activity is company‑specific.
None; AMLX trades primarily on US exchanges.
Minimal; the filing is a routine disclosure.
Counterpoint
The sale could be a routine liquidity move rather than a negative signal.
Key entities
- companyAmylyx Pharmaceuticals, Inc.
Biotech firm developing treatments for neurodegenerative diseases.
- personJoshua B. Cohen
Co‑Chief Executive Officer and director of AMLX.
